Results 91 to 100 of about 3,362,668 (327)

Neural Correlates of Cognitive Improvement After Virtual Reality‐Based Cognitive Remediation in Psychosis and Mood Disorders: A Randomized Controlled Trial

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Cognitive impairment in mood disorders and schizophrenia spectrum disorders hampers patients' clinical and functional outcomes. A key challenge in pro‐cognitive treatment development is the limited insight into the underlying neurocircuitry correlates of cognitive changes.
Viktoria Damgaard, Andreas Elleby Jespersen, Ida Kruse Søndergaard, Anders Lumbye, Maj Vinberg, Louise Birkedal Glenthøj, Merete Nordentoft, Anjali Sankar, Gitte Moos Knudsen, Julian Macoveanu, Kamilla Woznica Miskowiak   +10 more
wiley   +1 more source

Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent [PDF]

, 2000
Gary D. Tollefson, Cindy C. Taylor
openalex   +1 more source

Cognitive and Psychomotor Processing Speed in Medication‐Naïve Individuals With First‐Episode of Psychosis: The Role of Peripheral Inflammatory Markers

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background and Hypothesis Deficits in processing speed (PS) and psychomotor speed (PMS) are core cognitive impairments in schizophrenia spectrum disorders, including first‐episode psychosis (FEP). Neuroinflammation has been proposed as a potential contributor to these deficits.
Ángel Yorca‐Ruiz, Carlos Martínez Asensi, Rebeca Magdaleno Herrero, Alexandre Díaz‐Pons, Víctor Ortiz‐García de la Foz, Luis Manuel Fernández Cacho, Ana Catalán Alcantara, Benedicto Crespo‐Facorro, Rosa Ayesa‐Arriola   +8 more
wiley   +1 more source

Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis

Journal of the Formosan Medical Association, 2015
The USA Food and Drug Administration (FDA) issued warnings regarding the use of antipsychotics in patients with dementia in 2003 and 2005. We aimed to study the dose and duration of antipsychotic treatment in dementia, and to examine whether physicians ...
Yi-Ting Lin, Tzung-Jeng Hwang, Jia-Chi Shan, Huey-Ling Chiang, Yi-Han Sheu, Hai-Gwo Hwu   +5 more
doaj   +1 more source

Differential Treatment Responses in Pakistani Schizophrenia Samples: Correlation with Sociodemographic Parameters, Drug Addiction, Attitude to the Treatment and Antipsychotic Agents. [PDF]

Brain Sci, 2023
Habiba U, Malik A, Raja GK, Memon MR, Nizami ATD, Ishaq R, Ilyas M, Valadi H, Nawaz M, Shaiq PA.   +9 more
europepmc   +1 more source

Prefrontal cortex and reversion of atropine-induced disruption of the degraded contingency effect by antipsychotic agents and N-desmethylclozapine in rats [PDF]

, 2009
Sébastien Carnicella, Alexandre Mongeot, Jean‐Jacques Bourguignon, Philippe Oberling   +3 more
openalex   +1 more source

Associations Between Cognitive Functions and Subsequent Mood Disorder Prognosis in Low‐Risk, High‐Risk and Affected Monozygotic Twins: A Seven‐Year Follow‐Up Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Aberrant cognition is common among individuals at familial risk for mood disorders (MD) and those already affected. However, long‐term prospective studies are needed to determine whether specific cognitive features predict illness onset and relapse; and whether cognitive impairments reflect neurodevelopmental traits or ...
Kamilla Miskowiak, Hanne Lie Kjærstad, Stella Lystlund, Anjali Sankar, Lars Kessing, Maj Vinberg   +5 more
wiley   +1 more source

Discovery of novel arylpiperazine-based DA/5-HT modulators as potential antipsychotic agents – Design, synthesis, structural studies and pharmacological profiling

, 2023
Piotr Stępnicki, Katarzyna M. Targowska‐Duda, Antón L. Martínez, Agata Zięba, Olga Wronikowska‐Denysiuk, Martyna Z. Wróbel, Agata Bartyzel, Alicja Trzpil, Tomasz M. Wróbel, Andrzej Chodkowski, Karolina Mirecka, Tadeusz Karcz, Katarzyna Szczepańska, Marı́a Isabel Loza, Barbara Budzyńska, Jadwiga Turło, Jadwiga Handzlik, Emilia Fornal, Ewa Poleszak, Marián Castro, Agnieszka A. Kaczor   +20 more
openalex   +2 more sources

Influence of Sex and Diagnosis on Clinical Variables and Neurocognitive Performance in Severe Mental Illness. Results From the PsyCourse Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Bipolar disorder (BD) and schizophrenia (SZ) are serious mental illnesses (SMI) with overlapping symptoms but distinct differences in onset and course. Sex differences are an area of growing interest in SMI. This study aims to examine potential interactions between sex and diagnosis across a broad range of variables, to compare ...
Maria Serra‐Navarro, Maria Heilbronner, Brisa Solé, Roger Borràs, Anabel Martinez‐Arán, Kristina Adorjan, Alba Navarro‐Flores, Mojtaba Oraki Kohshour, Daniela Reich‐Erkelenz, Eva C. Schulte, Fanny Senner, Ion‐George Anghelescu, Volker Arolt, Bernhard T. Baune, Udo Dannlowski, Detlef E. Dietrich, Andreas J. Fallgatter, Christian Figge, Markus Jäger, Georg Juckel, Carsten Konrad, Jens Reimer, Eva Z. Reininghaus, Max Schmauß, Andrea Schmitt, Carsten Spitzer, Jens Wiltfang, Jörg Zimmermann, Sergi Papiol, Urs Heilbronner, Peter Falkai, Thomas G. Schulze, Eduard Vieta, Carla Torrent, Monika Budde, Silvia Amoretti   +35 more
wiley   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source